Patents by Inventor Peter Harwin

Peter Harwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treatment of thyroid eye disease
    Patent number: 12600788
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives and uses thereof are provided herein. Antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Grant
    Filed: June 18, 2025
    Date of Patent: April 14, 2026
    Assignee: Viridian Therapeutics, Inc.
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • Compositions and methods for treatment of thyroid eye disease
    Patent number: 12595309
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS), by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Grant
    Filed: November 8, 2024
    Date of Patent: April 7, 2026
    Assignee: Viridian Therapeutics, Inc.
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20250382374
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives and uses thereof are provided herein. Antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Application
    Filed: June 18, 2025
    Publication date: December 18, 2025
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE
    Publication number: 20250368733
    Abstract: Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.
    Type: Application
    Filed: June 10, 2025
    Publication date: December 4, 2025
    Inventors: Hussam H. SHAHEEN, Kenneth Evan THOMPSON, Peter HARWIN, Tomas KISELAK
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20250313639
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives and uses thereof are provided herein. Antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Application
    Filed: June 18, 2025
    Publication date: October 9, 2025
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • Compositions and methods for treatment of thyroid eye disease
    Patent number: 12404335
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Grant
    Filed: January 5, 2023
    Date of Patent: September 2, 2025
    Assignee: Viridian Therapeutics, Inc.
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • Antibodies that bind interleukin 13 and methods of use
    Patent number: 12358979
    Abstract: Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.
    Type: Grant
    Filed: December 13, 2024
    Date of Patent: July 15, 2025
    Assignee: Apogee Therapeutics, Inc.
    Inventors: Hussam H. Shaheen, Kenneth Evan Thompson, Peter Harwin, Tomas Kiselak
  • ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE
    Publication number: 20250129150
    Abstract: Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.
    Type: Application
    Filed: December 13, 2024
    Publication date: April 24, 2025
    Inventors: Hussam H. SHAHEEN, Kenneth Evan THOMPSON, Peter HARWIN, Tomas KISELAK
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20250059287
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: November 8, 2024
    Publication date: February 20, 2025
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20240043546
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: August 3, 2023
    Publication date: February 8, 2024
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20230279122
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: January 5, 2023
    Publication date: September 7, 2023
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • Compositions and methods for treatment of thyroid eye disease
    Patent number: 11548951
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS) in said subjects, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: January 10, 2023
    Assignee: VIRIDIAN THERAPEUTICS, INC.
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20230002495
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: August 29, 2022
    Publication date: January 5, 2023
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20220275096
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: April 20, 2022
    Publication date: September 1, 2022
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20220267451
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: October 14, 2021
    Publication date: August 25, 2022
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20220267450
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: October 14, 2021
    Publication date: August 25, 2022
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
    Publication number: 20220235137
    Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.
    Type: Application
    Filed: October 14, 2021
    Publication date: July 28, 2022
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao